Baidu
map

Radiother Oncol:功能影像学改变能预测晚期头颈部肿瘤患者对诱导化疗反应

2013-05-06 echo1166 互联网

在头颈部肿瘤患者进行放化疗前首先进行诱导化疗时,功能影像能反映患者对最优治疗计划的适应性。因此,理解诱导化疗对功能影像的影响是必要的。为了前瞻性的评估获得序列 FI(18F-FDG-PET, 弥散加权(DW)和动态对比增强(DCE) MRI)的可行性以及其在确定头颈部肿瘤患者诱导化疗后个体治疗方案中的作用。为了解答上述问题,Ceri Powell等进行了相关研究,研究结果发表在Radiother

在头颈部肿瘤患者进行放化疗前首先进行诱导化疗时,功能影像能反映患者对最优治疗计划的适应性。因此,理解诱导化疗对功能影像的影响是必要的。为了前瞻性的评估获得序列 FI(18F-FDG-PET, 弥散加权(DW)和动态对比增强(DCE) MRI)的可行性以及其在确定头颈部肿瘤患者诱导化疗后个体治疗方案中的作用。为了解答上述问题,Ceri Powell等进行了相关研究,研究结果发表在Radiother Oncol 10月的期刊上。

10名III期和IV期的头颈部肿瘤患者被纳入研究,他们接受常规影像学检查和功能性影像学检查,前者包括CT和MRI,后者包括DW、DCE-MRI和18F-FDG-PET/CT。评估时间为入组时和进行了2个周期的诱导化疗后、确定放化疗方案之前。

有一名患者因为幽闭恐惧症从研究中脱落。18F-FDG-PET影像显示9名患者中有7人对诱导化疗出现完全代谢应答。DCE-MRI显示传输常数显着降低以及在60s时钆曲线下面积,DW-MRI显示诱导化疗后ADC增高。

在头颈部肿瘤患者进行功能性影像学检查是可行的。在进行诱导化疗后出现显着的功能影像学参数的变化能指导帮助制定个体化的治疗方案

10.1016/j.radonc.2012.09.009
PMC:
PMID:

Changes in functional imaging parameters following induction chemotherapy have important implications for individualised patient-based treatment regimens for advanced head and neck cancer

Ceri Powella, Maria Schmidta, Marco Borria, Dow-Mu Koha, Mike Partridgea, Angela Riddella, Gary Cookd, Shreerang A. Bhidea, c, Christopher M. Nuttingb, Kevin J. Harringtonb, c, Katie L. Newbolda

Background When induction chemotherapy (IC) is used prior to chemoradiotherapy (CRT) in head and neck cancer (HNC), functional imaging (FI) may inform adaptation of treatment plans with the aim of optimising outcomes. Understanding the impact of IC on FI parameters is, therefore, essential. Purpose To prospectively evaluate the feasibility of acquiring serial FI (18F-FDG-PET, diffusion-weighted (DW) and dynamic contrast-enhanced (DCE) MRI) and its role in defining individualised treatment regimens following IC in HNC. Methods and materials Ten patients with stage III and IV HNC underwent conventional (CT and MRI) and functional (DW, DCE-MRI and 18F-FDG-PET/CT) imaging at baseline and following two cycles of IC prior to definitive CRT. Results One patient withdrew due to claustrophobia. Seven out of nine patients had a complete metabolic response to IC on 18F-FDG-PET imaging. DCE-MRI showed a significant fall in transfer constant (Ktrans) (0.209 vs 0.129 min−1P < 0.01) and integrated area under gadolinium curve at 60 s (IAUGC6O) (18.4 vs 11.9 mmol/min, P < 0.01) and DW-MRI a rise in ADC (0.89 vs 1.06 × 10−3 mm2/s, P < 0.01) following IC. Conclusions Acquiring FI sequences is feasible in HNC. There are marked changes in FI parameters following IC which may guide adaptation of individualised treatment regimens.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1792948, encodeId=57e31e92948fa, content=<a href='/topic/show?id=34211508e37' target=_blank style='color:#2F92EE;'>#Radiother#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15087, encryptionId=34211508e37, topicName=Radiother)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Sun Sep 15 15:56:00 CST 2013, time=2013-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864439, encodeId=77c61864439e7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Wed Nov 20 17:56:00 CST 2013, time=2013-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1973567, encodeId=cce519e35673f, content=<a href='/topic/show?id=41b03354870' target=_blank style='color:#2F92EE;'>#化疗反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33548, encryptionId=41b03354870, topicName=化疗反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Wed Feb 26 20:56:00 CST 2014, time=2014-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424119, encodeId=877b142411994, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Wed May 08 14:56:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491753, encodeId=96aa1491e53b0, content=<a href='/topic/show?id=b4f14442346' target=_blank style='color:#2F92EE;'>#头颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44423, encryptionId=b4f14442346, topicName=头颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2d8903151, createdName=wshxjq, createdTime=Wed May 08 14:56:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555650, encodeId=26071555650bf, content=<a href='/topic/show?id=fe2f918e29b' target=_blank style='color:#2F92EE;'>#诱导化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91872, encryptionId=fe2f918e29b, topicName=诱导化疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Wed May 08 14:56:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589672, encodeId=5b1a15896e201, content=<a href='/topic/show?id=124d10065220' target=_blank style='color:#2F92EE;'>#颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100652, encryptionId=124d10065220, topicName=颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46a17776631, createdName=木头人519, createdTime=Wed May 08 14:56:00 CST 2013, time=2013-05-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1792948, encodeId=57e31e92948fa, content=<a href='/topic/show?id=34211508e37' target=_blank style='color:#2F92EE;'>#Radiother#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15087, encryptionId=34211508e37, topicName=Radiother)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Sun Sep 15 15:56:00 CST 2013, time=2013-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864439, encodeId=77c61864439e7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Wed Nov 20 17:56:00 CST 2013, time=2013-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1973567, encodeId=cce519e35673f, content=<a href='/topic/show?id=41b03354870' target=_blank style='color:#2F92EE;'>#化疗反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33548, encryptionId=41b03354870, topicName=化疗反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Wed Feb 26 20:56:00 CST 2014, time=2014-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424119, encodeId=877b142411994, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Wed May 08 14:56:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491753, encodeId=96aa1491e53b0, content=<a href='/topic/show?id=b4f14442346' target=_blank style='color:#2F92EE;'>#头颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44423, encryptionId=b4f14442346, topicName=头颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2d8903151, createdName=wshxjq, createdTime=Wed May 08 14:56:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555650, encodeId=26071555650bf, content=<a href='/topic/show?id=fe2f918e29b' target=_blank style='color:#2F92EE;'>#诱导化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91872, encryptionId=fe2f918e29b, topicName=诱导化疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Wed May 08 14:56:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589672, encodeId=5b1a15896e201, content=<a href='/topic/show?id=124d10065220' target=_blank style='color:#2F92EE;'>#颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100652, encryptionId=124d10065220, topicName=颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46a17776631, createdName=木头人519, createdTime=Wed May 08 14:56:00 CST 2013, time=2013-05-08, status=1, ipAttribution=)]
    2013-11-20 minlingfeng
  3. [GetPortalCommentsPageByObjectIdResponse(id=1792948, encodeId=57e31e92948fa, content=<a href='/topic/show?id=34211508e37' target=_blank style='color:#2F92EE;'>#Radiother#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15087, encryptionId=34211508e37, topicName=Radiother)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Sun Sep 15 15:56:00 CST 2013, time=2013-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864439, encodeId=77c61864439e7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Wed Nov 20 17:56:00 CST 2013, time=2013-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1973567, encodeId=cce519e35673f, content=<a href='/topic/show?id=41b03354870' target=_blank style='color:#2F92EE;'>#化疗反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33548, encryptionId=41b03354870, topicName=化疗反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Wed Feb 26 20:56:00 CST 2014, time=2014-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424119, encodeId=877b142411994, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Wed May 08 14:56:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491753, encodeId=96aa1491e53b0, content=<a href='/topic/show?id=b4f14442346' target=_blank style='color:#2F92EE;'>#头颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44423, encryptionId=b4f14442346, topicName=头颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2d8903151, createdName=wshxjq, createdTime=Wed May 08 14:56:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555650, encodeId=26071555650bf, content=<a href='/topic/show?id=fe2f918e29b' target=_blank style='color:#2F92EE;'>#诱导化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91872, encryptionId=fe2f918e29b, topicName=诱导化疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Wed May 08 14:56:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589672, encodeId=5b1a15896e201, content=<a href='/topic/show?id=124d10065220' target=_blank style='color:#2F92EE;'>#颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100652, encryptionId=124d10065220, topicName=颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46a17776631, createdName=木头人519, createdTime=Wed May 08 14:56:00 CST 2013, time=2013-05-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1792948, encodeId=57e31e92948fa, content=<a href='/topic/show?id=34211508e37' target=_blank style='color:#2F92EE;'>#Radiother#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15087, encryptionId=34211508e37, topicName=Radiother)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Sun Sep 15 15:56:00 CST 2013, time=2013-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864439, encodeId=77c61864439e7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Wed Nov 20 17:56:00 CST 2013, time=2013-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1973567, encodeId=cce519e35673f, content=<a href='/topic/show?id=41b03354870' target=_blank style='color:#2F92EE;'>#化疗反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33548, encryptionId=41b03354870, topicName=化疗反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Wed Feb 26 20:56:00 CST 2014, time=2014-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424119, encodeId=877b142411994, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Wed May 08 14:56:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491753, encodeId=96aa1491e53b0, content=<a href='/topic/show?id=b4f14442346' target=_blank style='color:#2F92EE;'>#头颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44423, encryptionId=b4f14442346, topicName=头颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2d8903151, createdName=wshxjq, createdTime=Wed May 08 14:56:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555650, encodeId=26071555650bf, content=<a href='/topic/show?id=fe2f918e29b' target=_blank style='color:#2F92EE;'>#诱导化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91872, encryptionId=fe2f918e29b, topicName=诱导化疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Wed May 08 14:56:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589672, encodeId=5b1a15896e201, content=<a href='/topic/show?id=124d10065220' target=_blank style='color:#2F92EE;'>#颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100652, encryptionId=124d10065220, topicName=颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46a17776631, createdName=木头人519, createdTime=Wed May 08 14:56:00 CST 2013, time=2013-05-08, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1792948, encodeId=57e31e92948fa, content=<a href='/topic/show?id=34211508e37' target=_blank style='color:#2F92EE;'>#Radiother#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15087, encryptionId=34211508e37, topicName=Radiother)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Sun Sep 15 15:56:00 CST 2013, time=2013-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864439, encodeId=77c61864439e7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Wed Nov 20 17:56:00 CST 2013, time=2013-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1973567, encodeId=cce519e35673f, content=<a href='/topic/show?id=41b03354870' target=_blank style='color:#2F92EE;'>#化疗反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33548, encryptionId=41b03354870, topicName=化疗反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Wed Feb 26 20:56:00 CST 2014, time=2014-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424119, encodeId=877b142411994, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Wed May 08 14:56:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491753, encodeId=96aa1491e53b0, content=<a href='/topic/show?id=b4f14442346' target=_blank style='color:#2F92EE;'>#头颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44423, encryptionId=b4f14442346, topicName=头颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2d8903151, createdName=wshxjq, createdTime=Wed May 08 14:56:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555650, encodeId=26071555650bf, content=<a href='/topic/show?id=fe2f918e29b' target=_blank style='color:#2F92EE;'>#诱导化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91872, encryptionId=fe2f918e29b, topicName=诱导化疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Wed May 08 14:56:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589672, encodeId=5b1a15896e201, content=<a href='/topic/show?id=124d10065220' target=_blank style='color:#2F92EE;'>#颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100652, encryptionId=124d10065220, topicName=颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46a17776631, createdName=木头人519, createdTime=Wed May 08 14:56:00 CST 2013, time=2013-05-08, status=1, ipAttribution=)]
    2013-05-08 wshxjq
  6. [GetPortalCommentsPageByObjectIdResponse(id=1792948, encodeId=57e31e92948fa, content=<a href='/topic/show?id=34211508e37' target=_blank style='color:#2F92EE;'>#Radiother#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15087, encryptionId=34211508e37, topicName=Radiother)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Sun Sep 15 15:56:00 CST 2013, time=2013-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864439, encodeId=77c61864439e7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Wed Nov 20 17:56:00 CST 2013, time=2013-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1973567, encodeId=cce519e35673f, content=<a href='/topic/show?id=41b03354870' target=_blank style='color:#2F92EE;'>#化疗反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33548, encryptionId=41b03354870, topicName=化疗反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Wed Feb 26 20:56:00 CST 2014, time=2014-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424119, encodeId=877b142411994, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Wed May 08 14:56:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491753, encodeId=96aa1491e53b0, content=<a href='/topic/show?id=b4f14442346' target=_blank style='color:#2F92EE;'>#头颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44423, encryptionId=b4f14442346, topicName=头颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2d8903151, createdName=wshxjq, createdTime=Wed May 08 14:56:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555650, encodeId=26071555650bf, content=<a href='/topic/show?id=fe2f918e29b' target=_blank style='color:#2F92EE;'>#诱导化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91872, encryptionId=fe2f918e29b, topicName=诱导化疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Wed May 08 14:56:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589672, encodeId=5b1a15896e201, content=<a href='/topic/show?id=124d10065220' target=_blank style='color:#2F92EE;'>#颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100652, encryptionId=124d10065220, topicName=颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46a17776631, createdName=木头人519, createdTime=Wed May 08 14:56:00 CST 2013, time=2013-05-08, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1792948, encodeId=57e31e92948fa, content=<a href='/topic/show?id=34211508e37' target=_blank style='color:#2F92EE;'>#Radiother#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15087, encryptionId=34211508e37, topicName=Radiother)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Sun Sep 15 15:56:00 CST 2013, time=2013-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864439, encodeId=77c61864439e7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Wed Nov 20 17:56:00 CST 2013, time=2013-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1973567, encodeId=cce519e35673f, content=<a href='/topic/show?id=41b03354870' target=_blank style='color:#2F92EE;'>#化疗反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33548, encryptionId=41b03354870, topicName=化疗反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Wed Feb 26 20:56:00 CST 2014, time=2014-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424119, encodeId=877b142411994, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Wed May 08 14:56:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491753, encodeId=96aa1491e53b0, content=<a href='/topic/show?id=b4f14442346' target=_blank style='color:#2F92EE;'>#头颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44423, encryptionId=b4f14442346, topicName=头颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2d8903151, createdName=wshxjq, createdTime=Wed May 08 14:56:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555650, encodeId=26071555650bf, content=<a href='/topic/show?id=fe2f918e29b' target=_blank style='color:#2F92EE;'>#诱导化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91872, encryptionId=fe2f918e29b, topicName=诱导化疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Wed May 08 14:56:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589672, encodeId=5b1a15896e201, content=<a href='/topic/show?id=124d10065220' target=_blank style='color:#2F92EE;'>#颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100652, encryptionId=124d10065220, topicName=颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46a17776631, createdName=木头人519, createdTime=Wed May 08 14:56:00 CST 2013, time=2013-05-08, status=1, ipAttribution=)]

相关资讯

JAMA:乳腺造影联合超声波或MRI对乳腺癌高风险妇女有益

       据4月4日刊《美国医学会期刊》上的一项研究披露,在对那些乳腺癌风险增加且乳腺组织致密的妇女进行每年乳腺造影筛查之外再加上一种筛检性超声波检查或核磁共振成像(MRI)可令附带性发现乳腺癌的比率增加。(JAMA. 2012;307(13):1394-1404)        根据文章的背景资料:&l

Radiology:MRI显示偏头痛患者大脑皮质异常

MRI显示偏头痛患者皮质表面异常 意大利研究人员发现,遭受偏头痛的患者与从未有偏头痛的人相比,其处理疼痛的大脑区域的皮质厚度和表面积减少了。他们在《放射学杂志》上解释说,偏头痛患者的大脑异常可能在出生时就产生或随着时间的发展而产生。偏头痛是严重的、搏动性头痛,有时还伴有对光敏感、恶心甚至呕吐。在某些情况下,患者在头痛之前或期间经历了视觉功能(光环)的变化。根据WHO(世界卫生组织),全球超

基于多模式磁共振影像策略决定个体化溶栓时间窗

 急性缺血性卒中病因多种多样,加之患者病理生理状态个体差异较大,所以并非所有患者的治疗时间窗都相同。对急性卒中的影像和生物化学研究提示,有效治疗的时间窗在某些个体是可以延长的。影像技术作为有效的筛选手段旨在选择可能从溶栓中获益的患者,同时排除存在高度风险的患者群。 多模式影像策略在急性卒中临床试验中的作用 在治疗急性缺血性卒中的临床试验中,影像的作用(表1)可分为两个部分:一方面,

高血压脑损伤始于年轻时

  美国学者的研究表明,收缩压升高可造成年轻人出现隐匿性血管性脑损伤,这提示早期和良好血压控制的必要性。收缩压升高与颅脑磁共振成像(MRI)显示的局部各向异性分数降低和平均弥散率升高呈线性相关,尤其是前胼胝体、下额枕束和丘脑至额上回纤维;还与灰质容积减少显著相关。论文2012年11月2日在线发表于《柳叶刀·神经病学》(Lancet Neurol)杂志。

Neurology:MRI或可替代腰穿进行神经退行性疾病的鉴别

MRI预测tt/Aβ的精确度很高 尽管潜在的神经病理不同,阿尔茨海默病(AD)和额颞叶变性(FTLD)可能存在重叠的临床表现,鉴别诊断很困难,往往需要进行活检做病理学诊断或者进行腰穿脑脊液检查。为此,美国宾州大学神经科的Corey T. McMillan等人的一项研究,尝试用MRI替代脑脊液检查对神经退行性疾病进行鉴别,结果发现,MRI可以替代脑脊液生物标志物作为一种筛查AD和FTLD病理机

AAOS 2013:超声诊断半月板病变准确性超过MRI

 在2013年美国骨科医师学会年会(AAOS)上,来自美国的一项研究报告表明,超声是诊断半月板病变的一个有用工具,其潜在优势超过核磁共振成像(MRI)。   美国密苏里大学James L. Cook博士报告称,MRI通常被认为是半月板异常的金标准诊断显像模式,但它价格昂贵、不易获得大量患者,而且误诊率可达20%。   “超声检查可能是诊断半月板病变的一种有效工具,其潜在性克

Baidu
map
Baidu
map
Baidu
map